Kurz gefasst
Kommentar in der Zeitschrift Immunity, 2024. Verfasst von Andrew Y Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA…. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell. Die Arbeit nennt 10 Literaturangaben. Gefördert von: US Department of Defense, Jonsson Cancer Center Foundation, American Association for Cancer Research.
Abstract (Originalsprache)
Central tolerance restricts T cells that target self-antigens. In this issue of Immunity, Abdelfattah et al.1 describe a method to generate self-reactive T cell receptors (TCRs) by directed evolution of non-autoreactive TCRs to recognize self-antigen peptides and demonstrate potential for T cells engineered with such receptors in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Division of Surgical Oncology, Department of Surgery, David Gef…
- Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Microbiology, Immunology, and Molecular Genet…
Förderung
- US Department of Defense
- Jonsson Cancer Center Foundation
- American Association for Cancer Research
- Parker Institute for Cancer Immunotherapy
- California Institute for Regenerative Medicine
- Melanoma Research Alliance
Zitieren
APA
Hu, A. Y., & Puig-Saus, C. (2024). T-switch-ing TCR specificity. Immunity. https://doi.org/10.1016/j.immuni.2024.11.014
Vancouver
Hu AY, Puig-Saus C. T-switch-ing TCR specificity. Immunity. 2024. doi:10.1016/j.immuni.2024.11.014
BibTeX
@article{Hu2024,
author = {Hu, Andrew Y and Puig-Saus, Cristina},
title = {T-switch-ing TCR specificity},
journal = {Immunity},
year = {2024},
doi = {10.1016/j.immuni.2024.11.014}
}
EUVIMED